特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
963730

核酸医薬品の世界市場:COVID-19の影響を踏まえた考察と予測、2020年~2024年

Global Nucleic Acid Therapeutics Market (with Focus on Oligonucleotide): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

出版日: | 発行: Koncept Analytics | ページ情報: 英文 91 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
核酸医薬品の世界市場:COVID-19の影響を踏まえた考察と予測、2020年~2024年
出版日: 2020年10月12日
発行: Koncept Analytics
ページ情報: 英文 91 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の核酸医薬品市場は、2020年から2024年まで33.3%のCAGRで成長を続けると予測されており、2024年の市場規模は72億3,000万米ドルになる見通しです。市場拡大の原動力となるのは、がん患者数の増加、遺伝子治療の普及拡大、医薬品の研究開発費の増加、糖尿病の有病率の上昇、医療費の増加、核酸診断技術の急速な進歩などの要因です。

当レポートは、世界の核酸医薬品市場を調査したもので、新型コロナウイルス感染症(COVID-19)の影響、核酸医薬品とオリゴヌクレオチド製剤の市場分析、各地域市場の分析、市場の力学、企業プロファイルなどの情報を提供しています。

目次

第1章 概要

  • イントロダクション
  • DNAとRNAの違い
  • ヌクレオシド、ヌクレオチド、核酸
  • オリゴヌクレオチド
  • ASOとsiRNAのメカニズムの比較
  • 治療薬としての核酸
  • 核酸医薬品のカテゴリー
  • 遺伝子治療における核酸医薬品

第2章 COVID-19の影響

  • COVID-19検査の増加
  • COVID-19関連の研究開発資金の増加
  • COVID-19用の核酸ワクチン
  • オリゴヌクレオチドとCOVID-19パンデミック

第3章 世界の核酸医薬品市場の分析

  • 世界の核酸医薬品市場の現状と予測
  • 用途別の市場
    • 単一遺伝子核酸医薬品
    • 複数遺伝子核酸医薬品

第4章 世界のオリゴヌクレオチド製剤市場の分析

  • 世界のオリゴヌクレオチド製剤市場の現状と予測
  • 医薬品クラス別の市場
    • ASO(アンチセンスオリゴヌクレオチド)製剤
    • SiRNA(低分子干渉RNA)製剤

第5章 地域別の市場分析

  • 南北アメリカ
  • 欧州
  • アジア太平洋
  • 中東・アフリカ

第6章 市場の力学

  • 成長要因
    • 新たながん患者数の増加
    • 遺伝子治療の普及
    • 医薬品研究開発費の増加
    • 糖尿病有病率の上昇
    • 医療費の急増
    • 核酸診断技術の急速な進歩
  • 主なトレンド
    • 感染症分野の成長率の加速
    • 製薬業界とバイオテクノロジー業界での合併と買収の進展
    • 医療分野への政府支出の増加
    • 核酸医薬品の開発
  • 課題
    • 核酸医薬品のデリバリーの課題
    • RNAi治療薬開発のハードル
    • 法規制

    第7章 競合情勢

    • 主要企業の収益の比較
    • 主要企業の研究開発費の比較
    • 主要企業の時価総額の比較
    • 主要企業の核酸医薬品開発と特許ポートフォリオ

第8章 企業プロファイル

  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Benitec Biopharma
  • WAVE Life Sciences
  • Vir Biotechnology
  • Protagonist Therapeutics
図表

List of Figures

  • Nucleoside, Nucleotide & Nucleic Acid
  • COVID-19 Tests by Most Impacted Countries (2020)
  • Global Nucleic Acid Therapeutics Market by Value (2015-2019)
  • Global Nucleic Acid Therapeutics Market Forecast by Value (2020-2024)
  • Global Nucleic Acid Therapeutics Market Value by Application (2019)
  • Global Mono Genetic Nucleic Acid Therapeutics Market by Value (2015-2019)
  • Global Mono Genetic Nucleic Acid Therapeutics Market Forecast by Value (2020-2024)
  • Global Multi Genetic Nucleic Acid Therapeutics Market by Value (2015-2019)
  • Global Multi Genetic Nucleic Acid Therapeutics Market Forecast by Value (2020-2024)
  • Global Oligonucleotide Therapeutics Market by Value (2015-2019)
  • Global Oligonucleotide Therapeutics Market Forecast by Value (2020-2024)
  • Global Oligonucleotide Therapeutics Market Value by Drugs Class (2019)
  • Global ASO (Antisense Oligonucleotide) Therapeutics Market by Value (2015-2019)
  • Global ASO (Antisense Oligonucleotide) Therapeutics Market Forecast by Value (2020-2024)
  • Global SiRNA (Small interfering RNA) Therapeutics Market Forecast by Value (2017-2024)
  • Global Oligonucleotide Therapeutics Market Value by Regions (2019)
  • Americas Oligonucleotide Therapeutics Market Forecast by Value (2019-2024)
  • Europe Oligonucleotide Therapeutics Market Forecast by Value (2019-2024)
  • Asia Pacific Oligonucleotide Therapeutics Market Forecast by Value (2019-2024)
  • Middle East & Africa Oligonucleotide Therapeutics Market Forecast by Value (2019-2024)
  • Global New Cases of Top Cancer Types (2019)
  • Global Gene Therapy Market (2015-2019)
  • Global Pharmaceutical R&D Spending (2015-2019)
  • Global Diabetic Population (2010-2024)
  • Global Healthcare Expenditure Per Capita (2015-2019)
  • Global Growth Rate of Infectious Diseases Forecast (2017-2022)
  • Global Pharmaceutical and Biotech M&A (2015-2019)
  • Global Government Share on Health Spending (2019-2024)
  • FDA-Approved Nucleic Acid Therapeutics (2016-2019)
  • Alnylam Pharmaceuticals Revenue and Net Loss (2015-2019)
  • Alnylam Pharmaceuticals Revenue by Division (2019)
  • Arrowhead Pharmaceuticals Revenue and Net Income (Loss) (2015-2019)
  • Benitec Biopharma Revenue and Profit (Loss) (2015-2019)
  • Benitec Biopharma Revenue by Divisions (2019)
  • WAVE Life Sciences Revenues and Net Loss (2015-2019)
  • Vir Biotechnology Total Revenue and Net Loss (2017-2019)
  • Vir Biotechnology Total Revenue by Operations (2019)
  • Protagonist Therapeutics Revenue and Net Loss (2015-2019)

List of Tables

  • Difference Between DNA and RNA
  • Comparison of ASO and siRNA Mechanisms
  • Categories of Nucleic Acid Therapeutics
  • COVID-19 R&D Funding by Major Countries (2020)
  • mRNA Vaccine in Development for COVID-19
  • Key Players - Revenue Comparison (2019)
  • Key Players - R&D Expenditure Comparison (2019)
  • Key Players - Market Capitalization Comparison (2020)
  • Key Players - Nucleic Acid Drug Development and Patent Portfolio
目次

The global nucleic acid therapeutics market is expected to record a value of US$7.23 billion in 2024, increasing at a CAGR of 33.3%, for the duration spanning 2020-2024. The factors such as rising incidences of new cancer cases, rising penetration of gene therapy, increasing pharmaceutical R&D spending, rise in prevalence of diabetes, upsurge in healthcare expenditures and rapid advances in nucleic acid technologies for diagnostics would drive the growth of the market. However, the market growth would be challenged by the challenge of delivering nucleic acid therapeutics, development hurdles for RNAi therapeutics and legal regulations. A few notable trends may include, accelerating growth rates of infectious diseases, progress in pharmaceutical and biotech merger & acquisition, growth in government spending on healthcare and development of nucleic acid therapeutics.

The global nucleic acid therapeutics market holds a very lucrative scope as such class of compounds have emerged in recent years to yield extremely promising candidates for drug therapy to a wide range of diseases. Based on application, nucleic acid therapeutics are widely used for the treatment of mono-genetic disorders and multi-genetic disorders. The high prevalence of various monogenetic diseases is leading to the rising application of various nucleic acid therapeutics, which is likely to help in its market growth in future.

The fastest regional market was Americas due to the presence of major players and the well established R&D infrastructure, which helped in the development of various nucleic acid therapeutics. Further, owing to the sudden outbreak of COVID-19, scientists are evaluating various biomolecules and synthetic inhibitors against COVID-19; where the nucleic acid-based molecules may be considered as potential drug candidates, which is posing as an opportunity for the market growth of the nucleic acid therapeutics globally.

Scope of the report:

  • The report provides a comprehensive analysis of the global nucleic acid therapeutics market.
  • The major regional markets (Americas, Europe, Asia-Pacific and Middle East & Africa) have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Benitec Biopharma, WAVE Life Sciences, Vir Biotechnology and Protagonist Therapeutics) are also presented in detail.

Key Target Audience:

  • Nucleic Acid and Oligonucleotide Therapeutics Manufacturers
  • Pharmaceuticals and Biopharmaceutical Firms
  • End Users (Hospitals and Research Institutes)
  • Investment Banks
  • Healthcare and Medical Consultants.
  • Government Bodies & Regulating Authorities

Table of Contents

1. Overview

  • 1.1 Introduction
  • 1.2 Difference Between DNA and RNA
  • 1.3 Nucleoside, Nucleotide & Nucleic Acid
  • 1.4 Oligonucleotides
  • 1.5 Comparison of ASO and siRNA Mechanisms
  • 1.6 Nucleic Acid as Therapeutics
  • 1.7 Categories of Nucleic Acid Therapeutics
  • 1.8 Nucleic Acid Therapeutics in Gene Therapy

2. Impact of COVID-19

  • 2.1 Rise in COVID-19 Testing
  • 2.2 Growth in COVID-19 R&D Funding
  • 2.3 Nucleic Acid Vaccines for COVID-19
  • 2.4 Oligonucleotides and COVID-19 Pandemic

3. Global Nucleic Acid Therapeutics Market Analysis

  • 3.1 Global Nucleic Acid Therapeutics Market by Value
  • 3.2 Global Nucleic Acid Therapeutics Market Forecast by Value
  • 3.3 Global Nucleic Acid Therapeutics Market Value by Application
    • 3.3.1 Global Mono Genetic Nucleic Acid Therapeutics Market by Value
    • 3.3.2 Global Mono Genetic Nucleic Acid Therapeutics Market Forecast by Value
    • 3.3.3 Global Multi Genetic Nucleic Acid Therapeutics Market by Value
    • 3.3.4 Global Multi Genetic Nucleic Acid Therapeutics Market Forecast by Value

4. Global Oligonucleotide Therapeutics Market Analysis

  • 4.1 Global Oligonucleotide Therapeutics Market by Value
  • 4.2 Global Oligonucleotide Therapeutics Market Forecast by Value
  • 4.3 Global Oligonucleotide Therapeutics Market Value by Drugs Class
    • 4.3.1 Global ASO (Antisense Oligonucleotide) Therapeutics Market by Value
    • 4.3.2 Global ASO (Antisense Oligonucleotide) Therapeutics Market Forecast by Value
    • 4.3.3 Global SiRNA (Small interfering RNA) Therapeutics Market Forecast by Value
  • 4.4 Global Oligonucleotide Therapeutics Market Value by Regions

5. Regional Oligonucleotide Therapeutics Market Analysis

  • 5.1 Americas
    • 5.1.1 Americas Oligonucleotide Therapeutics Market Forecast by Value
  • 5.2 Europe
    • 5.2.1 Europe Oligonucleotide Therapeutics Market Forecast by Value
  • 5.3 Asia Pacific
    • 5.3.1 Asia Pacific Oligonucleotide Therapeutics Market Forecast by Value
  • 5.4 Middle East & Africa
    • 5.4.1 Middle East & Africa Oligonucleotide Therapeutics Market Forecast by Value

6. Market Dynamics

  • 6.1 Growth Drivers
    • 6.1.1 Rising Incidences of New Cancer Cases
    • 6.1.2 Rising Penetration of Gene Therapy
    • 6.1.3 Increasing Pharmaceutical R&D Spending
    • 6.1.4 Rise in Prevalence of Diabetes
    • 6.1.5 Upsurge in Healthcare Expenditures
    • 6.1.6 Rapid Advances in Nucleic Acid Technologies for Diagnostics
  • 6.2 Key Trends and Developments
    • 6.2.1 Accelerating Growth Rates of Infectious Diseases
    • 6.2.2 Progress in Pharmaceutical and Biotech Merger & Acquisition
    • 6.2.3 Growth in Government Spending on Healthcare
    • 6.2.4 Development of Nucleic Acid Therapeutics
  • 6.3 Challenges
    • 6.3.1 Challenge of Delivering Nucleic Acid Therapeutics
    • 6.3.2 Development Hurdles for RNAi Therapeutics
    • 6.3.3 Legal Regulations
  • 7.Competitive Landscape
  • 7.1 Global Market
    • 7.1.1 Key Players - Revenue Comparison
    • 7.1.2 Key Players - R&D Expenditure Comparison
    • 7.1.3 Key Players - Market Capitalization Comparison
    • 7.1.4 Key Players - Nucleic Acid Drug Development and Patent Portfolio

8. Company Profiles

  • 8.1 Alnylam Pharmaceuticals
    • 8.1.1 Business Overview
    • 8.1.2 Financial Overview
    • 8.1.3 Business Strategies
  • 8.2 Arrowhead Pharmaceuticals
    • 8.2.1 Business Overview
    • 8.2.3 Financial Overview
    • 8.3.3 Business Strategies
  • 8.3 Benitec Biopharma
    • 8.3.1 Business Overview
    • 8.3.2 Financial Overview
    • 8.3.3 Business Strategies
  • 8.4 WAVE Life Sciences
    • 8.4.1 Business Overview
    • 8.4.2 Financial Overview
    • 8.4.3 Business Strategies
  • 8.5 Vir Biotechnology
    • 8.5.1 Business Overview
    • 8.5.2 Financial Overview
    • 8.5.3 Business Strategies
  • 8.6 Protagonist Therapeutics
    • 8.6.1 Business Overview
    • 8.6.2 Financial Overview
    • 8.6.3 Business Strategies
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.